ATE132757T1 - Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit - Google Patents

Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit

Info

Publication number
ATE132757T1
ATE132757T1 AT91919614T AT91919614T ATE132757T1 AT E132757 T1 ATE132757 T1 AT E132757T1 AT 91919614 T AT91919614 T AT 91919614T AT 91919614 T AT91919614 T AT 91919614T AT E132757 T1 ATE132757 T1 AT E132757T1
Authority
AT
Austria
Prior art keywords
treatment
pharmaceutical preparation
clotting time
prolonged clotting
prolonged
Prior art date
Application number
AT91919614T
Other languages
English (en)
Inventor
Ole Nordfang
Ulla Hedner
Niels Peter Hundahl Moller
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE132757T1 publication Critical patent/ATE132757T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT91919614T 1990-10-31 1991-10-18 Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit ATE132757T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK261490A DK261490D0 (da) 1990-10-31 1990-10-31 New pharmaceutical compound

Publications (1)

Publication Number Publication Date
ATE132757T1 true ATE132757T1 (de) 1996-01-15

Family

ID=8113744

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919614T ATE132757T1 (de) 1990-10-31 1991-10-18 Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit

Country Status (15)

Country Link
EP (1) EP0558529B1 (de)
JP (1) JPH06502171A (de)
AT (1) ATE132757T1 (de)
AU (1) AU657926B2 (de)
CA (1) CA2095356A1 (de)
CZ (1) CZ282497B6 (de)
DE (1) DE69116380T2 (de)
DK (2) DK261490D0 (de)
ES (1) ES2083597T3 (de)
GR (1) GR3019514T3 (de)
HU (1) HUT64236A (de)
RU (1) RU2127600C1 (de)
SK (1) SK282516B6 (de)
UA (1) UA35567C2 (de)
WO (1) WO1992007584A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU636080B1 (en) * 1992-07-21 1993-04-08 Profy International Corporation Unitary loose sheet binder
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1282439B1 (de) * 2000-05-10 2005-11-30 Novo Nordisk Health Care AG PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR
PL372138A1 (en) 2001-10-15 2005-07-11 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
WO2007014749A2 (en) * 2005-07-29 2007-02-08 Universiteit Van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor
KR20110039218A (ko) 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항－인간 인터루킨－２０ 항체
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
KR101977846B1 (ko) * 2008-12-19 2019-05-14 박스알타 인코퍼레이티드 Tfpi 억제제 및 사용 방법
CN102325795B (zh) * 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EP3708190A1 (de) 2010-02-26 2020-09-16 Novo Nordisk A/S Stabile, antikörperhaltige zusammensetzungen
NZ602115A (en) 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
US9228022B2 (en) 2010-06-30 2016-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
TW201212938A (en) 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
NZ629130A (en) 2012-03-21 2016-10-28 Baxalta Inc Tfpi inhibitors and methods of use
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington A method of inhibiting the isolation of a purer tissue factor
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co ANDC of human tissue factor inhibitor
AU617795B2 (en) 1988-03-17 1991-12-05 Leukotech A/S Heparin-binding proteins, dna coding for them, processes for producing them as well as therapeutic preparations containing them
DK148890D0 (da) * 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat

Also Published As

Publication number Publication date
DE69116380D1 (de) 1996-02-22
HUT64236A (en) 1993-12-28
UA35567C2 (uk) 2001-04-16
RU2127600C1 (ru) 1999-03-20
SK282516B6 (sk) 2002-10-08
SK42893A3 (en) 1993-09-09
EP0558529B1 (de) 1996-01-10
CZ282497B6 (cs) 1997-07-16
ES2083597T3 (es) 1996-04-16
DK0558529T3 (da) 1996-06-03
CZ78693A3 (en) 1993-12-15
EP0558529A1 (de) 1993-09-08
HU9301253D0 (en) 1993-07-28
DK261490D0 (da) 1990-10-31
WO1992007584A1 (en) 1992-05-14
GR3019514T3 (en) 1996-07-31
AU657926B2 (en) 1995-03-30
DE69116380T2 (de) 1996-07-11
AU8871191A (en) 1992-05-26
CA2095356A1 (en) 1992-05-01
JPH06502171A (ja) 1994-03-10

Similar Documents

Publication Publication Date Title
ATE132757T1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
FI946004A (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
SE9404196D0 (sv) New antithrombotic formulation
DE3689943D1 (de) Degradierte Spezies eines Gewebeplasminogenaktivators, pharmazeutische Zubereitung und Verfahren zur Herstellung derselben.
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE109006T1 (de) Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen.
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
DE68905076T2 (de) Pharmazeutische Zusammensetzung für die Behandlung von Hautwunden.
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE70444T1 (de) Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen.
ATE128358T1 (de) Therapeutische mittel für diabetisches gangrän.
ATE71299T1 (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen.
DE68908445T2 (de) Mittel zur Behandlung von Lebererkrankungen.
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
DE69808663T2 (de) Neomycin/disaccharid wässerige lösung zur behandlung von enteroclysis bei hepatischer enzephalopathie
ATE218869T1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
DE9421606U1 (de) Vorrichtung zur extrakorporalen Behandlung von Blut
ATE5796T1 (de) Pharmazeutische zusammensetzung mit gehalt an l- alpha-methyl-3,4-dihydroxyphenylalanin und salicylamid zur behandlung hohen blutdrucks.
DE68905479T2 (de) Transdermate magensafthemmende wirkstoffe zur behandlung von magen-darm-erkrankungen.
UA7180C2 (uk) Препарат для лікування та профілактики атерогенних дисліпопротеїнемій та синдрому гіперкоагуляції

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee